Somewhat Favorable News Coverage Somewhat Unlikely to Impact Signal Genetics (MGEN) Share Price
News articles about Signal Genetics (NASDAQ:MGEN) have been trending somewhat positive on Sunday, Accern Sentiment reports. Accern rates the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Signal Genetics earned a media sentiment score of 0.05 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 46.7112032908901 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
A number of brokerages have weighed in on MGEN. Chardan Capital reiterated a “buy” rating on shares of Signal Genetics in a report on Monday, August 7th. Wedbush reiterated a “buy” rating on shares of Signal Genetics in a report on Friday, August 18th. Zacks Investment Research upgraded Signal Genetics from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a report on Tuesday, August 15th. Finally, ValuEngine downgraded Signal Genetics from a “hold” rating to a “sell” rating in a report on Wednesday, August 23rd. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $19.00.
Shares of Signal Genetics (MGEN) opened at 9.15 on Friday. Signal Genetics has a 52 week low of $0.12 and a 52 week high of $18.00. The stock has a 50 day moving average price of $10.02 and a 200 day moving average price of $11.58. The firm’s market capitalization is $196.57 million.
Signal Genetics (NASDAQ:MGEN) last issued its quarterly earnings data on Friday, August 11th. The medical research company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.13. The firm had revenue of $0.72 million during the quarter, compared to the consensus estimate of $0.46 million. Signal Genetics had a negative net margin of 770.31% and a negative return on equity of 92.62%. Analysts forecast that Signal Genetics will post ($1.52) EPS for the current year.
About Signal Genetics
Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.
Receive News & Ratings for Signal Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Signal Genetics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.